TW202342112A - 用於大規模合成放射性核素錯合物之方法 - Google Patents

用於大規模合成放射性核素錯合物之方法 Download PDF

Info

Publication number
TW202342112A
TW202342112A TW112104011A TW112104011A TW202342112A TW 202342112 A TW202342112 A TW 202342112A TW 112104011 A TW112104011 A TW 112104011A TW 112104011 A TW112104011 A TW 112104011A TW 202342112 A TW202342112 A TW 202342112A
Authority
TW
Taiwan
Prior art keywords
mother liquor
concentration
salt
target
iii
Prior art date
Application number
TW112104011A
Other languages
English (en)
Chinese (zh)
Inventor
多納托 巴巴托
瑞提雅 塔笛思可
米格爾 波
佛德瑞科 瓦樂瑞歐
瑪提雅 羅賽多
Original Assignee
法商高級催化劑應用品有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 法商高級催化劑應用品有限公司 filed Critical 法商高級催化劑應用品有限公司
Publication of TW202342112A publication Critical patent/TW202342112A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW112104011A 2022-02-04 2023-02-04 用於大規模合成放射性核素錯合物之方法 TW202342112A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263306822P 2022-02-04 2022-02-04
US63/306,822 2022-02-04

Publications (1)

Publication Number Publication Date
TW202342112A true TW202342112A (zh) 2023-11-01

Family

ID=85221934

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112104011A TW202342112A (zh) 2022-02-04 2023-02-04 用於大規模合成放射性核素錯合物之方法

Country Status (9)

Country Link
US (1) US20260053959A1 (enExample)
EP (1) EP4472678A1 (enExample)
JP (1) JP2025506322A (enExample)
KR (1) KR20240146015A (enExample)
CN (1) CN118159303A (enExample)
CA (1) CA3235923A1 (enExample)
IL (1) IL313964A (enExample)
TW (1) TW202342112A (enExample)
WO (1) WO2023148680A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025029946A1 (en) * 2023-07-31 2025-02-06 Curium Us Llc [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof
WO2025210599A2 (en) 2024-04-05 2025-10-09 Novartis Ag Combination therapies with dna damage response inhibitors and [ 177lu]lu-psma-617

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020021310A1 (en) * 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) Srl Stable, concentrated radionuclide complex solutions
LT4541381T (lt) * 2018-07-25 2026-03-25 Advanced Accelerator Applications S.A. Stabilūs, koncentruoti radionuklidų kompleksų tirpalai
EP3666451B1 (en) 2018-10-18 2021-03-03 Mitsubishi Electric Corporation Additive manufacturing machine and cooling method
CA3159337A1 (en) * 2018-10-31 2020-05-07 Advanced Accelerator Applications (Italy) Srl Methods for synthesis of radionuclide complex
SG11202113333SA (en) * 2019-06-14 2021-12-30 Edinburgh Molecular Imaging Ltd Compounds and methods of use

Also Published As

Publication number Publication date
JP2025506322A (ja) 2025-03-11
CA3235923A1 (en) 2023-08-10
KR20240146015A (ko) 2024-10-07
EP4472678A1 (en) 2024-12-11
US20260053959A1 (en) 2026-02-26
IL313964A (en) 2024-08-01
WO2023148680A1 (en) 2023-08-10
CN118159303A (zh) 2024-06-07

Similar Documents

Publication Publication Date Title
KR102767449B1 (ko) 방사성핵종 착물의 합성 방법
US12605447B2 (en) Stable formulations for radionuclide complexes
EP2190484B1 (en) Improved radiopharmaceutical composition
WO2020021310A1 (en) Stable, concentrated radionuclide complex solutions
TW202342112A (zh) 用於大規模合成放射性核素錯合物之方法
US20210379212A1 (en) Stable, concentrated radionuclide complex solutions
TW202123976A (zh) 穩定濃縮之放射性醫藥組合物
EP1901783B1 (en) Gentisic acid for stabilising 123-i radiopharmaceuticals
WO2017191604A2 (en) In-kit preparation of gallium-68 labelled radiopharmaceuticals
JPH07505621A (ja) 外科手術中における腫瘍組織の検出および探知法
RU2859685C2 (ru) Фармацевтическая композиция в форме раствора для внутривенного введения на основе металлокомплексов бета-эмиттеров: лютеций-177 или тербий-161 и агонистов соматостатиновых рецепторов: DOTA-TATE, DOTA-TOC, DOTA-NOC
RU2826739C2 (ru) Способы синтеза радионуклидного комплекса
WO2023164769A1 (en) Radiopharmaceutical and methods
WO2025030160A1 (en) Chelating compounds and methods of uses thereof
van Eerd-Vismale et al. Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats.